{
    "root": "a4b5ee2e-a273-4371-9477-8f84c83cc317",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Ticagrelor",
    "value": "20241220",
    "ingredients": [
        {
            "name": "TICAGRELOR",
            "code": "GLH0314RVC",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_68558"
        },
        {
            "name": "ANHYDROUS DIBASIC CALCIUM PHOSPHATE",
            "code": "L11K75P92J",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_77635"
        },
        {
            "name": "HYPROMELLOSE 2910 (3 MPA.S)",
            "code": "0VUT3PMY82",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "MANNITOL",
            "code": "3OWL53L36A",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_29864"
        },
        {
            "name": "POLYETHYLENE GLYCOL 4000",
            "code": "4R4HFI6D95",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "POVIDONE, UNSPECIFIED",
            "code": "FZ989GH94E"
        },
        {
            "name": "SODIUM STARCH GLYCOLATE TYPE A",
            "code": "H8AV0SQX4D",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_28017"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32178"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        }
    ],
    "indications": {
        "text": "ticagrelor p2y 12 platelet inhibitor indicated reduce risk cardiovascular ( cv ) death , myocardial infarction ( myocardial infarction ) , stroke patients acute coronary syndrome ( acs ) history myocardial infarction . least first 12 months following acs , superior clopidogrel . ticagrelor tablets also reduce risk stent thrombosis patients stented treatment acs . ( 1.1 ) reduce risk first myocardial infarction stroke patients coronary artery disease ( cad ) high risk events . limited setting , efficacy ticagrelor established population type 2 diabetes mellitus ( t2dm ) . ( 1.2 ) reduce risk stroke patients acute ischemic stroke ( nih stroke scale score \u22645 ) high-risk transient ischemic attack ( tia ) . ( 1.3 )",
        "doid_entities": [
            {
                "text": "myocardial infarction (DOID:5844)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_5844"
            },
            {
                "text": "stroke (DOID:6713)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_6713"
            },
            {
                "text": "syndrome (DOID:225)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_225"
            },
            {
                "text": "thrombosis (DOID:0060903)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_0060903"
            },
            {
                "text": "coronary artery disease (DOID:3393)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_3393"
            },
            {
                "text": "artery disease (DOID:0050828)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_0050828"
            },
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            },
            {
                "text": "type 2 diabetes mellitus (DOID:9352)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_9352"
            },
            {
                "text": "diabetes (DOID:9351)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_9351"
            },
            {
                "text": "transient ischemic attack (DOID:224)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_224"
            }
        ],
        "orphanet_entities": [
            {
                "disease": "acute ischemic stroke",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_439175"
            },
            {
                "disease": "acute coronary syndrome",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_454831"
            }
        ]
    },
    "contraindications": {
        "text": "acs history myocardial infarction initiate treatment 180 mg oral loading dose ticagrelor tablets . administer 90 mg twice daily first year . one year , administer 60 mg twice daily . ( 2.2 ) patients cad prior stroke myocardial infarction administer 60 mg ticagrelor tablets twice daily . ( 2.3 ) acute ischemic stroke initiate treatment 180 mg loading dose ticagrelor tablets continue 90 mg twice daily 30 days . ( 2.4 ) ticagrelor tablets daily maintenance dose aspirin 75 mg 100 mg. ( 2 ) however , patients undergone pci , consider single antiplatelet therapy ticagrelor tablets based evolving risk thrombotic versus bleeding events . ( 2.2 )",
        "doid_entities": [
            {
                "text": "myocardial infarction (DOID:5844)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_5844"
            },
            {
                "text": "stroke (DOID:6713)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_6713"
            }
        ],
        "orphanet_entities": [
            {
                "disease": "acute ischemic stroke",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_439175"
            }
        ]
    },
    "warningsAndPrecautions": "ticagrelor tablets available follows : 60 mg - light yellow yellow , oval shaped , film-coated tablet debossed \u201c 137 \u201d one side \u201c \u201d side . tablets supplied bottles 60 ( ndc 0480-2688-06 ) . 90 mg - light yellow yellow , round shaped , film-coated tablet debossed \u201c a91 \u201d one side plain side . tablets supplied bottles 60 ( ndc 0480-2695-06 ) . storage handling store 25\u00b0c ( 77\u00b0f ) ; excursions permitted 15\u00b0 30\u00b0c ( 59\u00b0 86\u00b0f ) [ usp controlled room temperature ] . dispense tight container defined usp .",
    "adverseReactions": "history intracranial hemorrhage . ( 4.1 ) active pathological bleeding . ( 4.2 ) hypersensitivity ticagrelor component product . ( 4.3 )",
    "indications_original": "Ticagrelor is a P2Y 12 platelet inhibitor indicated to reduce the risk of cardiovascular (CV) death, myocardial infarction (MI), and stroke in patients with acute coronary syndrome (ACS) or a history of MI. For at least the first 12 months following ACS, it is superior to clopidogrel. Ticagrelor tablets also reduce the risk of stent thrombosis in patients who have been stented for treatment of ACS. ( 1.1 ) to reduce the risk of a first MI or stroke in patients with coronary artery disease (CAD) at high risk for such events. While use is not limited to this setting, the efficacy of ticagrelor was established in a population with type 2 diabetes mellitus (T2DM). ( 1.2 ) to reduce the risk of stroke in patients with acute ischemic stroke (NIH Stroke Scale score \u22645) or high-risk transient ischemic attack (TIA). ( 1.3 )",
    "contraindications_original": "ACS or History of MI Initiate treatment with 180 mg oral loading dose of ticagrelor tablets. Then administer 90 mg twice daily during the first year. After one year, administer 60 mg twice daily. ( 2.2 ) Patients with CAD and No Prior Stroke or MI Administer 60 mg ticagrelor tablets twice daily. ( 2.3 ) Acute Ischemic Stroke Initiate treatment with a 180 mg loading dose of ticagrelor tablets then continue with 90 mg twice daily for up to 30 days. ( 2.4 ) Use ticagrelor tablets with a daily maintenance dose of aspirin of 75 mg to 100 mg. ( 2 ) However, in patients who have undergone PCI, consider single antiplatelet therapy with ticagrelor tablets based on the evolving risk for thrombotic versus bleeding events. ( 2.2 )",
    "warningsAndPrecautions_original": "Ticagrelor tablets are available as follows:\n                  60 mg - Light yellow to yellow, oval shaped, film-coated tablet debossed with \u201c137\u201d on one side and \u201cA\u201d on the other side. Tablets are supplied in bottles of 60 (NDC 0480-2688-06).\u00a0\n                  90 mg - Light yellow to yellow, round shaped, film-coated tablet debossed with \u201cA91\u201d on one side and plain on the other side. Tablets are supplied in bottles of 60 (NDC 0480-2695-06).\n                  \n                     Storage and Handling\n                  \n                  Store at 25\u00b0C (77\u00b0F); excursions permitted to 15\u00b0 to 30\u00b0C (59\u00b0 to 86\u00b0F) [see USP controlled room temperature].\n                  Dispense in a tight container as defined in the USP.",
    "adverseReactions_original": "History of intracranial hemorrhage. ( 4.1 ) Active pathological bleeding. ( 4.2 ) Hypersensitivity to ticagrelor or any component of the product. ( 4.3 )",
    "drug": [
        {
            "name": "Ticagrelor",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_68558"
        }
    ]
}